Moderate growth is expected from vascular and diagnostics division (excluding to certain royalty and supply arrangement revenues and currency impact), after the company launched various products including its next-generation Drug Eluting Stent XIENCE Xpedition and XIENCE PRIME in different parts of the world.
FORBES: Abbott Earnings Preview: What We Are Watching